文献速递乳腺MRUS

磁共振引导超声及后续超声引导活检对可疑乳腺磁共振表现的准确性

Accuracy of MRI-directed ultrasound and subsequent ultrasound-guided biopsy for suspicious breast MRI findings.
PubMed 文献 · Clin Radiol · 2019-11-23

该回顾性研究纳入2009年1月1日至2012年3月30日连续7,332例增强MRI检查,评估MRI引导超声及后续超声引导空心针活检的准确性。298例发现推测超声相关病灶,221例(73.4%)接受活检;随访MRI示83例良性活检病灶中活检夹准确72例(87%)、不准确11例(13%),作者认为对MRI引导超声相关性不确定者应行MRI引导活检。

要点

  • MRI引导超声发现推测超声相关病灶后,73.4%(221/298)接受了超声引导空心针活检。
  • 随访MRI显示活检夹准确87%(72/83),不准确13%(11/83)。
  • 11例不准确病灶中6例后续组织学诊断,其中1/6(16.7%)为恶性。

核心结论

  • MRI引导超声是评估MRI表现可靠且准确的方法,但MRI引导超声引导活检的不准确率为13%。
  • 作者认为,对于MRI引导超声相关性不确定的病例,应行MRI引导活检以获得准确及时的诊断。

研究设计与样本

  • 回顾性研究,经机构审查委员会批准并符合HIPAA,纳入2009年1月1日至2012年3月30日连续7,332例增强MRI检查。
  • 识别接受MRI引导超声、超声引导空心针活检及良性活检后随访MRI的MRI检出病灶,检查由医师共识判读。
  • 以随访MRI上活检夹位于MRI病灶1 cm以内视为超声引导空心针活检准确。

关键影像表现/征象

  • 522例患者因MRI检出病灶行MRI引导超声。
  • 298例发现推测的超声相关病灶,其中221例(73.4%)接受活检。
  • 90例良性且一致的活检病灶行超声引导空心针活检后随访MRI,7例因后续MRI未见活检标记物被排除。
  • 剩余83例中,随访MRI显示活检标记物准确72例(87%),不准确11例(13%)。

诊断标准与关键数值

  • 超声引导空心针活检准确性标准:随访MRI上活检夹位于MRI病灶1 cm以内为准确。
  • 不准确11例中,5例根据随访MRI稳定或消退判为良性,6例接受后续组织学诊断(平均至组织学诊断时间13个月),其中1/6(16.7%)为恶性。

临床应用与阅片要点

  • 作者认为,对于MRI引导超声相关性不确定的病例,应行MRI引导活检以获得准确及时的诊断。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To determine the accuracy of magnetic resonance imaging (MRI)-directed breast ultrasound and subsequent ultrasound-guided biopsy, and to evaluate patient and lesion factors associated with the detection of an ultrasound correlate for MRI findings.

MATERIALS AND METHODS: Health Insurance Portability and Accountability Act (HIPAA)-compliant, institutional review board-approved retrospective review of 7,332 consecutive contrast-enhanced MRI examinations from 1 January 2009 to 30 March 2012 was performed to identify MRI-detected lesions that underwent MRI-directed ultrasound, ultrasound-guided core-needle biopsy (USG-CNB), and follow-up MRI after benign biopsy. Examinations were reviewed in consensus. USG-CNB was considered accurate if the biopsy clip was within 1 cm of the MRI lesion on follow-up MRI. Medical records were reviewed for histopathology, patient demographics, and follow-up imaging.

RESULTS: MRI-directed ultrasound was performed on 522 patients with MRI-detected findings. A presumed ultrasound correlate was identified in 298 cases and 221 (73.4%) underwent biopsy. Follow-up MRI after USG-CNB was performed for 90 benign concordant biopsied lesions. Seven lesions were excluded because the biopsy marker was not visible on the subsequent MRI examination. Of the remaining 83 lesions, the biopsy marker was accurate in 72 (87%) lesions on follow-up MRI and 11 were considered inaccurate (13%). Of these 11 lesions, five were considered benign based on stability/resolution at follow-up MRI, while six underwent subsequent tissue diagnosis (mean time to tissue diagnosis: 13 months), with 1/6 (16.7%) malignancies.

CONCLUSION: Although MRI-directed ultrasound is a reliable and accurate method to evaluate MRI findings, a 13% inaccuracy rate for MRI-directed ultrasound-guided biopsy was found. Therefore, for cases with uncertain MRI-directed ultrasound correlation, MRI-guided biopsy should be performed for accurate and timely diagnosis.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Chikarmane SA, Jin B, Giess CS, et al. Accuracy of MRI-directed ultrasound and subsequent ultrasound-guided biopsy for suspicious breast MRI findings. Clin Radiol. 2019. PMID: 31767141. doi:10.1016/j.crad.2019.10.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。